PF-Atlas › Clinical Trials › NCT02626182

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

sildenafil · Phase 1

Registry ID
NCT02626182
Phase
Phase 1
Status
Completed
Drug / intervention
sildenafil
Sponsor
National Jewish Health
Start
2015-12
Enrollment
14
Locations
1

About this trial

This study evaluates the ability of the drug sildenafil to improved exercise capacity, cardiac performance during exercise, and quality of life in patients with moderate to severe CF lung disease. 3/4 of the subjects will receive sildenafil and 1/4 will receive placebo.

View NCT02626182 on ClinicalTrials.gov →

Explore related

All sildenafil trialsAll IPF trials

Related trials

sildenafil — NCT00359736Sildenafil — NCT00352482sildenafil — NCT00659529Sildenafil — NCT01194232Sildenafil — NCT02057458Sildenafil — NCT00981747
Medical disclaimer. This page summarizes public trial data for NCT02626182 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.